280 related articles for article (PubMed ID: 33893941)
1. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.
Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X
Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941
[TBL] [Abstract][Full Text] [Related]
2. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
[TBL] [Abstract][Full Text] [Related]
3. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
4. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
5. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract][Full Text] [Related]
7. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
8. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.
Wong D; Yip S; Sorensen PH
Pathol Oncol Res; 2020 Jul; 26(3):1385-1399. PubMed ID: 31256325
[TBL] [Abstract][Full Text] [Related]
9. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
10. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
11. Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors.
Zhu L; Hobbs B; Roszik J; Holla V; Hong DS
Invest New Drugs; 2022 Feb; 40(1):157-162. PubMed ID: 34341905
[TBL] [Abstract][Full Text] [Related]
12. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
13. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
14. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
15. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Laetsch TW; Hong DS
Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
[TBL] [Abstract][Full Text] [Related]
16. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract][Full Text] [Related]
17. Phase separation underlies signaling activation of oncogenic NTRK fusions.
Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
[No Abstract] [Full Text] [Related]
18. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
19. NTRK-Fusions - A new kid on the block.
Märkl B; Hirschbühl K; Dhillon C
Pathol Res Pract; 2019 Oct; 215(10):152572. PubMed ID: 31400924
[TBL] [Abstract][Full Text] [Related]
20. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
[Next] [New Search]